Poor
Mostly Disaligned
Patient Risk:
Moderate
Summary
Most statements are general/off-label-style assertions that are not supported by the provided label text. Only transplant prophylaxis/in immunosuppression-related framing is supported; claims about treating autoimmune diseases and chemotherapy/rapidly dividing cells are not supported by the supplied prescribing information.
Category Scores
Accurate Statements
Clinicians use mycophenolate to prevent organ rejection after transplant by suppressing the immune response.
Supported for prophylaxis of organ rejection in allogeneic kidney, heart, and liver transplant recipients (Section 1 INDICATIONS AND USAGE) and consistent with the label’s mechanism describing inhibition of DNA synthesis/lymphocyte effects (Section 12 CLINICAL PHARMACOLOGY).
MYHIBBIN is indicated for prophylaxis of organ rejection in adult and pediatric (≥3 months) recipients of allogeneic kidney, heart, or liver transplants, in combination with other immunosuppressants.
Directly supported by Section 1 INDICATIONS AND USAGE.
Mycophenolate’s routine prescribing role is immunosuppression.
The label indicates use as part of immunosuppressive regimens for prophylaxis of organ rejection (Section 1 INDICATIONS AND USAGE).
Mycophenolate comes in different forms, including mycophenolate mofetil and mycophenolate sodium.
Partially supported: the provided label text explicitly references mycophenolate mofetil (MMF) and mycophenolic acid (MPA). The excerpt provided does not mention mycophenolate sodium.
Unsupported Statements
Mycophenolate is most commonly used as an immunosuppressant.
The supplied label does not provide any statements about “most common” usage patterns.
Mycophenolate is used to treat certain autoimmune diseases.
The supplied label excerpt includes only prophylaxis of organ rejection after allogeneic kidney, heart, or liver transplant (Section 1 INDICATIONS AND USAGE) and does not support autoimmune disease treatment indications.
Mycophenolate can affect cells that rapidly divide.
While the label describes inhibition of DNA synthesis and effects on lymphocytes, the supplied excerpt does not use the phrasing/claim “rapidly dividing cells.”
Medications that affect rapidly dividing cells are sometimes grouped in casual conversation with chemotherapy.
The supplied prescribing information does not discuss chemotherapy classification or casual-conversation grouping.
Clinical use and labeling matter: mycophenolate is generally prescribed to control immune activity rather than to treat cancer.
The label excerpt does not state anything about being “generally prescribed” vs cancer treatment in the manner claimed.
Clinicians use mycophenolate to treat autoimmune conditions where the immune system is overactive.
Autoimmune indication is not supported in the provided label excerpt.
Some drugs that suppress rapidly dividing cells are used both in oncology and other settings.
The supplied label excerpt does not make this general comparison statement.
If mycophenolate is being used for cancer treatment in a specific case, that would be an exception that depends on the exact regimen and diagnosis.
The supplied label excerpt does not mention cancer treatment use of mycophenolate or provide support for any exception framework.
Mycophenolate is usually not classified as a chemotherapy drug.
The supplied label excerpt does not address chemotherapy classification.
Mycophenolate is used to treat certain autoimmune diseases.
Not supported by provided label (no autoimmune indications listed).
Mycophenolate’s routine prescribing role is immunosuppression.
Partially supported (transplant prophylaxis in immunosuppressive regimens), but “routine prescribing role” is broader than the provided label excerpt.
Mycophenolate comes in different forms, including mycophenolate mofetil and mycophenolate sodium.
The provided label excerpt mentions mycophenolate mofetil and oral suspension (MMF) but does not mention mycophenolate sodium.
Contradictions
Low
AI Statement
Mycophenolate is used to treat certain autoimmune diseases.
Label Reference
Section 1 INDICATIONS AND USAGE (provided excerpt).
Low
AI Statement
Clinical use and labeling matter: mycophenolate is generally prescribed to control immune activity rather than to treat cancer.
Label Reference
Section 1 INDICATIONS AND USAGE (provided excerpt).
Important Omissions
No adverse reaction/monitoring/warnings details were provided to contextualize risks in the statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported claims (autoimmune/cancer/chemotherapy framing) could mislead about indications; the label excerpt supports transplant prophylaxis and includes malignancy risk and other warnings, but the AI assertions largely omit label-specific safety context.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Disaligned
Primary Issue
Multiple statements are not supported by the provided prescribing information (autoimmune disease treatment; cancer/chemotherapy classification; “mycophenolate sodium” form; “most common” usage).
Suggested Improvement
Limit claims to on-label indications and mechanisms explicitly present in the provided label excerpt (prophylaxis of organ rejection in allogeneic kidney/heart/liver transplant recipients ≥3 months, in combination with other immunosuppressants; contraindication to hypersensitivity; immunosuppressant-associated malignancy risk; and MMF/MPA mechanism). Remove unsupported references to autoimmune or cancer use and chemotherapy classification unless the provided label text supports them.